Blackstone announced on March 21 2026 that it is exploring a sale of its clinical‑trial business, Nucleus Network, a move that could attract interest from private‑equity firms and global contract research organizations.
Nucleus Network was acquired by Blackstone in October 2021 for approximately $700 million and had generated about $40 million in EBITDA at that time. Since the acquisition, Blackstone has grown the earnings of the business, and the current valuation is expected to exceed $1 billion.
The potential sale is part of Blackstone’s broader portfolio optimization strategy, which has focused on divesting mature assets to concentrate on core asset‑management, AI infrastructure, real estate, and private credit. The company’s statement notes that the divestiture would streamline its portfolio and allow it to focus on its core businesses.
Interest has been expressed by several private‑equity firms, including Kohlberg & Company, Bain Capital, Advent International, and EQT, as well as global CROs such as Syneos Health. EQT’s interest is notable because it already owns Parexel, a contract research organization.
The sale would also address regulatory concerns. Blackstone’s indirect ownership of Nucleus Network and its potential acquisition of I'rom Group (owner of CMAX Clinical Research) prompted an Australian Competition and Consumer Commission review, which required Blackstone to divest CMAX to avoid competition concerns in the Australian phase‑1 clinical trial market.
While no market reaction data is available, the announcement signals that Blackstone is actively seeking exits for mature assets and that the clinical‑trial site network sector remains attractive to private‑equity investors, reflecting ongoing consolidation in the industry.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.